Magnetic Resonance Imaging Study of JM-4 in Multiple Sclerosis/Clinically Patients
Status:
Unknown status
Trial end date:
2020-03-15
Target enrollment:
Participant gender:
Summary
This is a Phase 0/1 study of MS patients to determine the safety and potential efficacy of a
novel, small human peptide designated as JM-4. The study will involve treatment for 5-7 days
with JM-4 to determine the effects of Gadolinium(+) lesion number and volume in the brains of
patients.